Pei‐Ru Li

Key safety outcomes of SGLT2 inhibitors versus DPP ‐4 inhibitors in general and vulnerable participants with T2DM : A target trial emulation study

Abstract Aims Sodium–glucose cotransporter‐2 inhibitors (SGLT2i), a class of oral hypoglycaemic agents (OHAs), have demonstrated cardiovascular and renal benefits. However, safety concerns may hinder their broader adoption, particularly among frail populations. We evaluated key s...